Results 61 to 70 of about 10,751 (182)

Efficacy and Safety of ramucirumab Combined With Nab‐paclitaxel, Lobaplatin, and S‐1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS‐01 Trial

MedComm, Volume 7, Issue 11, November 2026.
This study enrolled 70 HER2‐negative, unresectable stage III/IV gastric/gastroesophageal junction adenocarcinoma patients with over 6‐month survival, divided into RNPLS and NPLS groups (n = 35 each). Both groups received 21‐day‐cycle chemotherapy with lobaplatin, nab‐paclitaxel, and S‐1, while RNPLS additionally used ramucirumab.
Juan Wang, Wei Wang, Guanghui Xu, Shushang Liu, Longxing Jiao, Shu Wang, Chaosheng Peng, Yuxuan Ma, Xin Liu, Huade Huo, Haolin Li, Xiaohua Li, Jianjun Yang   +12 more
wiley   +1 more source

Ramucirumab : the long and winding road toward being an option for mCRC treatment

, 2019
: Introduction: Colorectal cancer (CRC) is one of the main causes of cancer-related morbidity and mortality worldwide. Mortality is most often attributable to metastatic disease.
Fano, Carolina, Fassan, Matteo, Alberti, Giulia, Gallimberti, Sara, Loupakis, Fotios, Murgioni, Sabina, Ahcene-Djaballah, Selma, Lonardi, Sara, Daniel, Francesca, Magro, Cristina, Debeuckelaere, Celine, Girardi, Noemi, Prenen, Hans, Fassan M., Alberti G., Magro C., Gallimberti S., Debeuckelaere C., Loupakis F., Ahcene-Djaballah S., Prenen H., Lonardi S., Daniel F., Fano C., Girardi N., Murgioni S.   +25 more
core   +2 more sources

Gastric Cancer: Epidemiology, Risk Factors, Pathogenesis, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 11, November 2026.
This comprehensive review summarizes gastric cancer epidemiology, multifactorial risk factors (like infectious, dietary, genetic), pathogenesis such as precancerous evolution, molecular alterations, and a focus on the bidirectional interactions between gastric cancer cells and macrophages in the tumor microenvironment.
Yixuan Xin, Xingya Wang, Yangtao Wu, Qian Liu, Qian Ren, Hui Wang, Jingbo Zhai   +6 more
wiley   +1 more source

Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial

Genome Medicine, 2021
Background Gastric cancer (GC) is a heterogenous disease consisted of several subtypes with distinct molecular traits. The clinical implication of molecular classification has been limited especially in association with treatment efficacy of ramucirumab ...
Seung Tae Kim, Jason K. Sa, Sung Yong Oh, Kyung Kim, Jung Yong Hong, Won Ki Kang, Kyoung-Mee Kim, Jeeyun Lee   +7 more
doaj   +1 more source

Supplementary Figure from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy

, 2022
Supplementary Figure from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based ...
Shalini Makawita (7515581), Sunyoung Lee (767697), Priya Bhosale (15031842), Ahmed Shalaby (5917118), Kavitha Reddy (216962), Shubham Pant (696486), Milind Javle (15045399), Robert A. Wolff (11900049), Kanwal Raghav (3172167), Rachna T. Shroff (12122310), Lianchun Xiao (266594), Anaemy Danner De Armas (15045396)   +11 more
core   +2 more sources

KRAS G12Y Causing a False‐Positive KRAS G12C Result With an Indistinguishable PCR Pattern in Lung Adenocarcinoma

Respirology Case Reports, Volume 14, Issue 11, November 2026.
A KRAS G12Y‐mutated lung adenocarcinoma yielded a false‐positive KRAS G12C reaction on the AmoyDx Pan Lung Cancer PCR Panel, whereas NGS‐based comprehensive genomic profiling identified KRAS G12Y with no sequence reads supporting KRAS G12C. A KRAS G12Y plasmid reproduced the same qualitative PCR reaction pattern as genuine KRAS G12C, demonstrating ...
Tsugumi Iwasaki, Hiroaki Ikushima, Mikako Nakamura, Yu Mikami, Kousuke Watanabe, Masanori Kawakami, Akihisa Mitani, Hidenori Kage   +7 more
wiley   +1 more source

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

, 2022
The RANGE study (NCT02426125) evaluated ramucirumab (an anti-VEGFR2 monoclonal antibody) in patients with platinum-refractory advanced urothelial carcinoma (UC).
Rasmussen, E.R., Castellano, D., de Wit, R., Drakaki, A., Aragon-Ching, J.B., Gakis, G., van der Heijden, M.S., Rhodes, R., Hozak, R.R., Powles, T., Eigl, B.J., Aggarwal, A., Petrylak, D., Matsubara, N., Sternberg, C.N., Necchi, A., Wijayawardana, S., Tagawa, S.T., Nishiyama, H., Hussain, S.A., Vaishampayan, U., Lee, J.-L., Bamias, A., Xia, M.S., Bell-McGuinn, K.M.   +24 more
core   +1 more source

Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study

Scientific Reports
The combination of trifluridine/tipiracil hydrochloride (FTD/TPI) plus ramucirumab has demonstrated clinical activity in patients with advanced gastric cancer (AGC).
Yukiya Narita, Takatsugu Ogata, Yasunobu Ishizuka, Tomoki Sakakida, Munehiro Wakabayashi, Hiroyuki Kodama, Kazunori Honda, Toshiki Masuishi, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Masahiro Tajika, Kei Muro   +12 more
doaj   +1 more source

Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma

Медицинский совет, 2018
Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2. In two randomised clinical trials Ramucirumab either alone or in combination with paclitaxel has been found to be safe and effective for patients with ...
T. A. Titova, N. S. Besova, V. A. Gorbunova, Yu. P. Kuvshinov, A. A. Filatov, A. F. Ketsba, A. A. Fedenko   +6 more
doaj   +1 more source

Ischemic stroke in a patient with EGFR‐mutated non–small‐cell lung cancer after treatment with ramucirumab

Thoracic Cancer, 2022
Vascular endothelial growth factor (VEGF) inhibitors have been widely investigated in the last 10 years, with particular attention paid to their adverse effects because of their efficacy in improving cancer patient survival.
Guo‐Yu Chen, Wen‐Chien Cheng, Chih‐Yen Tu   +2 more
doaj   +1 more source